Skip to main content
MEMPHASYS LIMITED. logo

MEMPHASYS LIMITED. — Investor Relations & Filings

Ticker · MEM ISIN · AU000000MEM5 LEI · 549300RZ3LBXHF3WXL97 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,221 across all filing types
Latest filing 2008-10-09 Capital/Financing Update
Country AU Australia
Listing ASX MEM

About MEMPHASYS LIMITED.

https://www.memphasys.com/

Memphasys Limited is a biotechnology company specializing in the development of advanced cell separation and reproductive biotechnology solutions. The company's core technology platform utilizes proprietary membranes and electrophoresis to isolate high-quality cells from biological fluids. Its flagship product, the Felix™ system, is an automated device designed for the rapid separation of high-quality sperm from semen samples for use in human assisted reproductive technology (ART) procedures. This technology aims to improve clinical outcomes by selecting sperm with lower DNA fragmentation and higher motility compared to traditional centrifuge-based techniques. Beyond human fertility, the company applies its bio-separation expertise to animal health, including diagnostic tools for stallion fertility. Memphasys focuses on providing innovative solutions that enhance efficiency and success rates in the global reproductive health market.

Recent filings

Filing Released Lang Actions
First Sale of the High Margin MF10 in the US 2 pages ?Kb
Capital/Financing Update Classification · 85% confidence The document is a press release announcing the first US sale of a product (MF10) by NuSep. It contains promotional and sales information, product descriptions, and company background. There are no financial statements, regulatory disclosures, or detailed financial performance data. The document length is 3273 characters, which is relatively short and typical for a press release. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is an announcement related to company sales and product updates, which aligns best with a Capital/Financing Update (CAP) as it relates to business development and sales milestones that could impact company financing or capital outlook. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2008-10-09 English
Update on $25m Acquisition of NxGen 10 pages ?Kb
Regulatory Filings
2008-10-01 English
Announces $25m Binding HOA to Acquire NxGen 2 pages ?Kb
Capital/Financing Update Classification · 95% confidence The document is a press release announcing a binding Heads of Agreement (HOA) for NuSep to acquire NxGen Pharmaceuticals for $25 million. It includes financial highlights of NxGen, details about the acquisition terms, and background information about both companies. There is no detailed financial report, audit, or regulatory filing included. The document is an announcement of a capital transaction (acquisition) and financing through share issuance. This fits the category of Capital/Financing Update (CAP) as it provides an update on a significant financing and acquisition activity involving share issuance and capital structure changes.
2008-09-30 English
NuSep Board and Management Update 1 page ?Kb
Board/Management Information Classification · 100% confidence The document is titled 'Board and Management Update' and announces the appointment of Mr John Manusu as Executive Chairman and Dr Hari Nair as Managing Director. It provides background information about the company NuSep and its products but does not contain financial data, regulatory certifications, or detailed reports. The content focuses on changes in the company's board and senior management. The document length is short (2491 characters), consistent with a management announcement rather than a full report or presentation. Therefore, the document fits the category of Board/Management Information (MANG).
2008-09-30 English
Annual Report 64 pages ?Kb
Regulatory Filings
2008-09-29 English
Director Appointment/Resignation 3 pages ?Kb
Director's Dealing Classification · 100% confidence The document is an announcement regarding the resignation of a director, Nicholas Care, from the board of NuSep. It includes details about the director's resignation, thanks, and a notice of the director's securities interests (Appendix 3Z). There is no financial data, earnings, or report content. The focus is on board/management changes and director interests. This fits the category of Board/Management Information (MANG) and Director's Dealing (DIRS). However, since the primary purpose is the appointment/resignation of a director and the attached Appendix 3Z is a Director's Interest Notice (a form of director's dealing), the best classification is Director's Dealing (DIRS).
2008-09-18 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.